Event List
retrieve:
Return the details about the given Event id.
list:
List all Event objects.
GET /api/v1/events/?format=api&offset=60&ordering=-description
{ "count": 217, "next": "https://memento.epfl.ch/api/v1/events/?format=api&limit=10&offset=70&ordering=-description", "previous": "https://memento.epfl.ch/api/v1/events/?format=api&limit=10&offset=50&ordering=-description", "results": [ { "id": 71948, "title": "U.S. CDMRP – Lung Cancer Research Program | Research Funding", "slug": "us-cdmrp-lung-cancer-research-program-research-f-6", "event_url": "https://memento.epfl.ch/event/us-cdmrp-lung-cancer-research-program-research-f-6", "visual_url": "https://memento.epfl.ch/image/33256/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33256/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33256/max-size.jpg", "lang": "en", "start_date": "2026-06-23", "end_date": "2026-06-23", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Lung Cancer Research Program</strong> <strong>(LCRP)</strong> Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Idea Development Award</strong> Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.</li>\r\n\t<li>The <strong>Patient-Centered Outcomes and Survivorship Award</strong> Supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications.</li>\r\n\t<li>The <strong>Translational Research Award</strong> mechanism supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application.</li>\r\n</ul>\r\nAll applications for LCRP funding must specifically address at least one of the <strong>Areas of Emphasis</strong>. The FY26 LCRP Areas are listed at the end of this announcement.<br>\r\n<br>\r\n<strong>Funding</strong>: <br>\r\nIdea Development Award: max. $800K<br>\r\nPatient-Centered Outcomes and Survivorship Award: max. $975K<br>\r\nTranslational Research Award: $1.35M – $1.85M<br>\r\n<sup><sub>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sub></sup><br>\r\n<br>\r\n<strong>Duration</strong>: <br>\r\nIdea Development Award: 3 years<br>\r\nPatient-Centered Outcomes and Survivorship Award: 3 years<br>\r\nTranslational Research Award: 3-4 years<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Program-specific seniority levels and eligibility criteria are further defined within each award mechanism <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221239&fileType=pdf\">here</a>.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: </strong>\r\n\r\n<ul>\r\n\t<li><strong>23 June 2026, </strong>5:00 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Idea Development Award</li>\r\n\t\t<li>Translational Research Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>18 August 2026, </strong>5:00 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Patient-Centered Outcomes and Survivorship Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<strong>Full Application Deadline for all calls</strong>:\r\n\r\n<ul>\r\n\t<li><strong>02 September 2026</strong>, 11:59 p.m Eastern Time</li>\r\n</ul>\r\n <br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719103\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221239&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a></li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Idea Development Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221233&fileType=pdf\">HT942526LCRPIDA</a></li>\r\n\t\t<li>Patient-Centered Outcomes and Survivorship Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221308&fileType=pdf\">HT942526LCRPPCOSA</a></li>\r\n\t\t<li>Translational Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36221292&fileType=pdf\">HT942526LCRPTRA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>FY26 LCRP Areas of Emphasis</strong>\r\n\r\n<ul>\r\n\t<li>Biology and Etiology\r\n\t<ul>\r\n\t\t<li>Understand the molecular mechanisms of initiation and progression of pre-malignancy to lung cancer.</li>\r\n\t\t<li>Understand contributors to lung cancer development other than tobacco, including hereditary and sex-specific differences.</li>\r\n\t\t<li>Understand the biology of metastatic/oligometastatic disease progression.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Prevention and Risk Reduction\r\n\t<ul>\r\n\t\t<li>Identify innovative strategies for the prevention and/or interception of lung cancer development.</li>\r\n\t\t<li>Identify innovative strategies for the prevention of recurrence or metastases from lung cancer.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Detection, Diagnosis and Surveillance\r\n\t<ul>\r\n\t\t<li>Improve and expand approaches to screening and early detection of lung cancer.</li>\r\n\t\t<li>Identify strategies for prompt detection and/or characterization of progressive disease.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Treatment and Prognosis\r\n\t<ul>\r\n\t\t<li>Identify innovative strategies for the treatment of lung cancer, including overcoming resistance.</li>\r\n\t\t<li>Develop or optimize biomarkers to assist with therapeutic decision-making.</li>\r\n\t\t<li>Enhance the understanding, detection, and treatment of brain and leptomeningeal metastases in lung cancer.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>Health Outcomes and Survivorship\r\n\t<ul>\r\n\t\t<li>Identify and understand the long-term and cumulative effects of lung cancer and its treatment(s) on quality of life for patients and families.</li>\r\n\t\t<li>Identify and understand the impact of comorbidities on survivorship care in all stages of lung cancer.</li>\r\n\t\t<li>Reduce differences among high-risk groups and populations.</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>", "image_description": "", "creation_date": "2026-05-26T19:15:50", "last_modification_date": "2026-05-26T19:15:50", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120861/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api", "https://memento.epfl.ch/api/v1/mementos/140/?format=api" ] }, { "id": 71900, "title": "U.S. CDMRP – Breast Cancer Research Program | Research Funding", "slug": "us-cdmrp-breast-cancer-research-program-research-5", "event_url": "https://memento.epfl.ch/event/us-cdmrp-breast-cancer-research-program-research-5", "visual_url": "https://memento.epfl.ch/image/33218/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33218/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33218/max-size.jpg", "lang": "en", "start_date": "2026-06-12", "end_date": "2026-06-12", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Breast Cancer Research Program</strong> <strong>(BCRP)</strong> Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Breakthrough Awards</strong> supports promising research that has high potential to lead to or make breakthroughs in breast cancer. The Breakthrough Award is structured with four different funding levels. Each level has a defined research scope :\r\n\t<ul>\r\n\t\t<li><u>Funding Level 1</u>: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem.</li>\r\n\t\t<li><u>Funding Level 2</u>: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.</li>\r\n\t\t<li><u>Funding Level 3</u><strong>: </strong>Advanced translational studies with a high degree of project readiness.</li>\r\n\t\t<li><u>Funding Level 4</u><strong>: </strong>Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required.</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li>The <strong>Clinical Research Extension Award</strong> aims to extend the data collection, follow-up, and analysis of breast cancer clinical research studies. Proposed research may entail a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial.</li>\r\n\t<li>The <strong>Era of Hope Scholar Award</strong> supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s)</li>\r\n\t<li>The <strong>Transformative Breast Cancer Consortium Award</strong> is designed to support large-scale, multidisciplinary and multi-institutional consortia that address major challenges in breast cancer through tightly integrated and collaborative research efforts. It enables up to five Principal Investigators, including a Consortium Director, to work within a coordinated framework where all project components are aligned toward a shared central hypothesis. The award specifically aims to foster innovative and paradigm-shifting approaches that go beyond the capabilities of individual laboratories, requiring strong integration across scientific, administrative, and logistical aspects, as well as the active involvement of breast cancer advocates and cross-disciplinary expertise.</li>\r\n\t<li>The <strong>Transformative Breast Cancer Consortium Development Award</strong> is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY26 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s).</li>\r\n</ul>\r\n<br>\r\nAll applications must align with at least one BCRP Overarching Challenge. The FY26 BCRP Challenges are listed at the end of this announcement.<br>\r\n<br>\r\n<strong>Funding</strong>: <br>\r\nBreakthrough 1: $750K - $1.25M<br>\r\nBreakthrough 2: $1.65M - $3.35M<br>\r\nBreakthrough 3: $5.6M - $7M<br>\r\nBreakthrough 4: max. $21M<br>\r\nClinical Research Extension: $7M - $8.4M<br>\r\nEra of Hope: max. $4.9M<br>\r\nTransformative Breast Cancer Consortium Award: max. $35M<br>\r\nTransformative Breast Cancer Consortium Development Award: max. $140K<br>\r\n<sub>Note: Cost caps are <strong><em>total costs (direct plus indirect costs).</em> </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding.</sub><br>\r\n<br>\r\n<strong>Duration</strong>: <br>\r\nBreakthrough 1: 3 years<br>\r\nBreakthrough 2: 3-4 years<br>\r\nBreakthrough 3: 4 years<br>\r\nBreakthrough 4: 4 years<br>\r\nClinical Research Extension: 4 years<br>\r\nEra of Hope: 4 years<br>\r\nTransformative Breast Cancer Consortium Award: 4 years<br>\r\nTransformative Breast Cancer Consortium Development Award: 1 year<br>\r\n<br>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Programme-specific seniority levels are further defined <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241307&fileType=pdf\">here</a>.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: </strong>\r\n\r\n<ul>\r\n\t<li><strong>12 June 2026, </strong>5:00 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Breakthrough Award Level 3</li>\r\n\t\t<li>Breakthrough Award Level 4</li>\r\n\t\t<li>Transformative Breast Cancer Consortium Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>24 June 2026, </strong>5:00 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Breakthrough Award Level 1-2</li>\r\n\t\t<li>Transformative Breast Cancer Consortium Development Award</li>\r\n\t\t<li>Clinical Research Extension Award</li>\r\n\t\t<li>Era of Hope Scholar Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>Full Application Deadline</strong>: \r\n\r\n<ul>\r\n\t<li><strong>08 July 2026, </strong>11:59 p.m. Eastern time\r\n\r\n\t<ul>\r\n\t\t<li>Breakthrough Award Level 1-2</li>\r\n\t\t<li>Transformative Breast Cancer Consortium Development Award</li>\r\n\t\t<li>Clinical Research Extension Award</li>\r\n\t\t<li>Era of Hope Scholar Award</li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><strong>30 September 2026, </strong>11:59 p.m. Eastern time\r\n\t<ul>\r\n\t\t<li>Breakthrough Award Level 3</li>\r\n\t\t<li>Breakthrough Award Level 4</li>\r\n\t\t<li>Transformative Breast Cancer Consortium Award</li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=705101\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241307&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Breakthrough 1: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855304&fileType=doc&otherMimeType=application/msword\">HT942526BCRPBTA12</a></li>\r\n\t\t<li>Breakthrough 2: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855304&fileType=doc&otherMimeType=application/msword\">HT942526BCRPBTA12</a></li>\r\n\t\t<li>Breakthrough 3: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855250&fileType=doc&otherMimeType=application/msword\">HT942526BCRPBTA3</a></li>\r\n\t\t<li>Breakthrough 4: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855218&fileType=doc&otherMimeType=application/msword\">HT942526BCRPBTA4</a></li>\r\n\t\t<li>Clinical Research Extension: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855261&fileType=doc&otherMimeType=application/msword\">HT942526BCRPCREA</a></li>\r\n\t\t<li>Era of Hope: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855289&fileType=doc&otherMimeType=application/msword\">HT942526BCRPEOHS</a></li>\r\n\t\t<li>Transformative Breast Cancer Consortium Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35853313&fileType=doc&otherMimeType=application/msword\">HT942526BCRPTBCCA</a></li>\r\n\t\t<li>Transformative Breast Cancer Consortium Development Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35855260&fileType=doc&otherMimeType=application/msword\">HT942526BCRPTBCCDA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n<br>\r\n<strong>FY26 BCRP Overarching Challenges</strong>\r\n\r\n<ul>\r\n\t<li>Prevent breast cancer (primary prevention)</li>\r\n\t<li>Identify determinants of breast cancer initiation, risk, or susceptibility</li>\r\n\t<li>Distinguish deadly from non-deadly breast cancers</li>\r\n\t<li>Conquer the problems of overdiagnosis and overtreatment</li>\r\n\t<li>Identify what drives breast cancer growth; determine how to stop it</li>\r\n\t<li>Identify why some breast cancers become metastatic</li>\r\n\t<li>Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence</li>\r\n\t<li>Revolutionize treatment regimens by replacing them with ones that do all of the following: improve survival, are more effective, and are less toxic</li>\r\n\t<li>Eliminate the mortality associated with metastatic breast cancer</li>\r\n</ul>\r\nAlternatively, with adequate justification, applications may identify and address another overarching challenge related to <a href=\"https://cdmrp.health.mil/bcrp/pdfs/BreastCancerLandscape2025.pdf\">The Breast Cancer Landscape</a>. Justification must be provided in the application.<br>\r\n ", "image_description": "", "creation_date": "2026-05-18T19:01:58", "last_modification_date": "2026-05-18T19:01:58", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120797/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api", "https://memento.epfl.ch/api/v1/mementos/140/?format=api" ] }, { "id": 71949, "title": "U.S. CDMRP – Amyotrophic Lateral Sclerosis Research Program | Research Funding", "slug": "us-cdmrp-amyotrophic-lateral-sclerosis-research--4", "event_url": "https://memento.epfl.ch/event/us-cdmrp-amyotrophic-lateral-sclerosis-research--4", "visual_url": "https://memento.epfl.ch/image/33257/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33257/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33257/max-size.jpg", "lang": "en", "start_date": "2026-06-24", "end_date": "2026-06-24", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Amyotrophic Lateral Sclerosis Research Program (ALSRP) </strong>Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Clinical Outcomes and Biomarkers Award </strong>supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Applications must address at least one of the focus areas listed <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35925310&fileType=pdf\">here</a>.</li>\r\n\t<li>The <strong>Pilot Clinical Trial Award </strong>supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or symptom management of ALS. Proposed projects may range from phase 1 to small-scale phase 2 trials. Applications must address at least one of the focus areas listed <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35927287&fileType=pdf\">here</a>.</li>\r\n\t<li>The <strong>Therapeutic Development Award </strong>supports research ranging from preclinical validation of therapeutic leads through FDA IND-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology. Candidate therapeutics that already have been granted an IND are not appropriate for the TDA.</li>\r\n\t<li>The <strong>Therapeutic Idea Award </strong>supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation.</li>\r\n</ul>\r\n<strong>Funding</strong>: \r\n\r\n<ul>\r\n\t<li>Clinical Outcomes and Biomarkers Award: max. $1M</li>\r\n\t<li>Pilot Clinical Trial Award: max. $2.8M</li>\r\n\t<li>Therapeutic Development Award: max. $2M</li>\r\n\t<li>Therapeutic Idea Award: max. $840K</li>\r\n</ul>\r\n<sup>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sup><br>\r\n<br>\r\n<strong>Duration</strong>: \r\n\r\n<ul>\r\n\t<li>Clinical Outcomes and Biomarkers Award: 3 years</li>\r\n\t<li>Pilot Clinical Trial Award: 3 years</li>\r\n\t<li>Therapeutic Development Award: 3 years</li>\r\n\t<li>Therapeutic Idea Award: 2 years</li>\r\n</ul>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: 24 June 2026, </strong>5:00 p.m. Eastern time<br>\r\n<strong>Full Application Deadline</strong>: <strong>30 September 2026</strong>, 11:59 p.m Eastern Time<br>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=707101\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241278&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a>.</li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Clinical Outcomes and Biomarkers Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35925310&fileType=pdf\">HT942526ALSRPCOBA</a></li>\r\n\t\t<li>Pilot Clinical Trial Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35927287&fileType=pdf\">HT942526ALSRPPCTA</a></li>\r\n\t\t<li>Therapeutic Development Award : <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35921227&fileType=pdf\">HT942526ALSRPTDA</a></li>\r\n\t\t<li>Therapeutic Idea Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=35919305&fileType=pdf\">HT942526ALSRPTIA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>", "image_description": "", "creation_date": "2026-05-26T19:57:31", "last_modification_date": "2026-05-26T19:57:31", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120862/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api", "https://memento.epfl.ch/api/v1/mementos/140/?format=api" ] }, { "id": 71922, "title": "U.S. CDMRP – Alzheimer's Research Program | Research Funding", "slug": "us-cdmrp-alzheimer-s-research-program-research-fun", "event_url": "https://memento.epfl.ch/event/us-cdmrp-alzheimer-s-research-program-research-fun", "visual_url": "https://memento.epfl.ch/image/33239/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33239/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33239/max-size.jpg", "lang": "en", "start_date": "2026-06-22", "end_date": "2026-06-22", "start_time": null, "end_time": null, "description": "<strong>Aim</strong>: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 <strong>Alzheimer's Research Program (AZRP) </strong>Awards. Several award programs are available:\r\n<ul>\r\n\t<li>The <strong>Transforming Care Award </strong>aims to support well-designed, non-incremental clinical research that develops and implements interventions, innovations, and solutions to address critical challenges in dementia care. Projects should lead to improved quality of life, reduced caregiver burden and stress, and enhanced care delivery and outcomes for individuals living with AD/ADRD.</li>\r\n\t<li>The <strong>Transforming Diagnosis Award </strong>supports non-incremental, solution-oriented research that addresses critical barriers to timely and accurate diagnosis, disease monitoring, and prognosis in AD/ADRD. Projects should demonstrate clear potential to improve accessibility, clinical implementation, and the reliability of diagnostic and prognostic approaches.</li>\r\n\t<li>The <strong>Transforming Research Award </strong>supports non-incremental, high-impact research that aims to drive transformative advances in reducing risk and preventing the development of AD/ADRD. Projects should demonstrate strong potential to accelerate prevention strategies and deliver meaningful improvements in patient outcomes and quality of life.<strong> </strong>All projects must respond to one of the focus areas listed <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241238&fileType=pdf\">here</a>.</li>\r\n</ul>\r\n<strong>Funding</strong>:\r\n\r\n<ul>\r\n\t<li>Transforming Care Award: $1.6M - $1.9M</li>\r\n\t<li>Transforming Diagnosis Award: $1.5M - $1.7M</li>\r\n\t<li>Transforming Research Award: max. $1M</li>\r\n</ul>\r\n<br>\r\n<sub>Note: Cost caps are <strong>total costs (direct plus indirect costs). </strong>In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding</sub><br>\r\n<br>\r\n<br>\r\n<strong>Duration</strong>: \r\n\r\n<ul>\r\n\t<li>Transforming Care Award: 4 years</li>\r\n\t<li>Transforming Diagnosis Award: 4 years</li>\r\n\t<li>Transforming Research Award: 3 years</li>\r\n</ul>\r\n<strong>Eligibility: </strong>Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Program-specific seniority levels and eligibility criteria are further defined within each award mechanism <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243245&fileType=pdf\">here</a>.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Pre-applications are submitted through the <a href=\"https://ebrap.org/eBRAP/public/index.htm\">eBRAP platform</a>. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.<br>\r\n<br>\r\n<strong>Pre-Application Deadline: 22 June 2026, </strong>5:00 p.m. Eastern time<br>\r\n<strong>Full Application Deadline</strong>: <strong>24 September 2026</strong>, 11:59 p.m Eastern Time<br>\r\n<br>\r\n<strong>Further information:</strong>\r\n\r\n<ul>\r\n\t<li>To find the full program announcements and to start your pre-application see <a href=\"https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=719106\">here</a></li>\r\n\t<li>A useful summary of each call can be found <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36243245&fileType=pdf\">here</a></li>\r\n\t<li>For questions about the eBRAP or Grants.gov platforms, contact the <a href=\"mailto:[email protected]\">Research Office</a></li>\r\n\t<li>Grants.gov Funding Opportunity Numbers:\r\n\t<ul>\r\n\t\t<li>Transforming Care Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241229&fileType=pdf\">HT942526AZRPTRCA</a></li>\r\n\t\t<li>Transforming Diagnosis Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241231&fileType=pdf\">HT942526AZRPTRDA</a></li>\r\n\t\t<li>Transforming Research Award: <a href=\"https://ebrap.org/eBRAP/public/ViewFile.htm?fileId=36241238&fileType=pdf\">HT942526AZRPTRRA</a></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>", "image_description": "", "creation_date": "2026-05-21T16:12:42", "last_modification_date": "2026-05-21T16:12:42", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120829/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/9/?format=api", "https://memento.epfl.ch/api/v1/mementos/140/?format=api" ] }, { "id": 71809, "title": "SERI – Leading House MENA | Research Partnership Grants 2026", "slug": "seri-leading-house-mena-research-partnership-gra-3", "event_url": "https://memento.epfl.ch/event/seri-leading-house-mena-research-partnership-gra-3", "visual_url": "https://memento.epfl.ch/image/33132/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33132/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33132/max-size.jpg", "lang": "en", "start_date": "2026-06-26", "end_date": "2026-06-26", "start_time": null, "end_time": null, "description": "<strong>Aim:</strong><br>\r\nThis instrument aims to strengthen collaboration between researchers based in Switzerland and those in partner countries from the MENA region. The program will support either the launch of new joint projects or the consolidation of existing initiatives. Open to all scientific disciplines, the call welcomes a wide range of methods and approaches: field research, feasibility studies, qualitative interviews, artistic or design-based research, etc.<br>\r\n<br>\r\n<strong>Amount :</strong> Max. CHF 25,000 per project<br>\r\n<strong>Deadline :</strong> 23.06.2026<br>\r\n<strong>Duration :</strong> up to 12 months<br>\r\n<strong>Eligibility criteria</strong><br>\r\nApplicants must hold a position (permanent or lasting until the end of the project) in an eligible institution and demonstrate at least three years of research or relevant professional experience. What it meant by eligible institutions: \r\n<ul>\r\n\t<li>for <strong><em>Switzerland</em> - </strong>accredited higher education institutions (list provided by <a href=\"https://www.swissuniversities.ch/en/topics/studying/accredited-swiss-higher-education-institutions\" target=\"_blank\">swissuniversities</a>) and research institutions as defined in art. 4. and 5. of the <a href=\"https://www.fedlex.admin.ch/eli/cc/2013/786/en\" target=\"_blank\">RIPA</a></li>\r\n\t<li>for <strong><em>MENA region</em>: </strong>accredited universities and public research institutes</li>\r\n</ul>\r\n<br>\r\n<strong>Further information</strong>\r\n\r\n<ul>\r\n\t<li>Please consider that The RPG 2026 will open soon and the detailed guidelines will be available on the <a href=\"https://www.hes-so.ch/en/hes-so/about-us/international/leading-house-mena/research-partnership-grants-2026\">main page</a> of the call</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li>For more specific guidelines or questions about relevance, applicants are encouraged to contact <a href=\"mailto:[email protected]\">Leading House MENA</a></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li>Any other questions may be addressed to the <a href=\"mailto:[email protected]\">Research Office</a></li>\r\n</ul>", "image_description": "", "creation_date": "2026-05-05T17:28:59", "last_modification_date": "2026-05-05T17:28:59", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120665/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/3/?format=api", "https://memento.epfl.ch/api/v1/mementos/4/?format=api", "https://memento.epfl.ch/api/v1/mementos/5/?format=api", "https://memento.epfl.ch/api/v1/mementos/6/?format=api", "https://memento.epfl.ch/api/v1/mementos/8/?format=api", "https://memento.epfl.ch/api/v1/mementos/9/?format=api", "https://memento.epfl.ch/api/v1/mementos/27/?format=api", "https://memento.epfl.ch/api/v1/mementos/140/?format=api" ] }, { "id": 71727, "title": "NovoNordisk Fonden – Challenge Programme 2027", "slug": "novonordisk-fonden-challenge-programme-2027", "event_url": "https://memento.epfl.ch/event/novonordisk-fonden-challenge-programme-2027", "visual_url": "https://memento.epfl.ch/image/33051/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33051/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33051/max-size.jpg", "lang": "en", "start_date": "2026-10-07", "end_date": "2026-10-07", "start_time": null, "end_time": null, "description": "<strong>Aim: </strong> The The Novo Nordisk Foundation (NNF) Program aims to support outstanding, collaborative research projects addressing major challenges within human health and the sustainability of society and the planet. The program is designed to enable ambitious, long‑term, interdisciplinary research efforts that bring together leading researchers around a clearly defined scientific challenge within selected thematic areas.<br>\r\n<br>\r\nNNF is pleased to announce the release of the below calls on April, 22 (*):<br>\r\n \r\n<ul>\r\n\t<li><strong><a href=\"https://novonordiskfonden.dk/grant/challenge-programme-2027-advancing-next-generation-amr-diagnostics-for-lower-respiratory-tract-infections/\">Advancing Next Generation AMR Diagnostics for Lower Respiratory Tract Infections</a></strong><br>\r\n\tSupporting interdisciplinary proof‑of‑concept research aimed at developing rapid, accurate and affordable diagnostic solutions for lower respiratory tract infections, with a focus on improving clinical decision‑making and combating antimicrobial resistance.</li>\r\n\t<li><strong><a href=\"https://novonordiskfonden.dk/grant/challenge-programme-2027-heat-and-hypertension-understanding-the-mechanisms-of-interaction/\">Heat and Hypertension – Understanding the Mechanisms of Interaction</a></strong><br>\r\n\tFocusing on mechanistic research to elucidate how heat exposure affects individuals with hypertension, integrating cellular, animal and human studies with the aim of improving prevention, treatment and clinical management during extreme heat events.</li>\r\n\t<li><strong><a href=\"https://novonordiskfonden.dk/grant/challenge-programme-2027-unravelling-electron-transfer-mechanisms-in-hybrid-bio-electrocatalysis/\">Unravelling Electron Transfer Mechanisms in Hybrid Bio‑Electrocatalysis</a></strong><br>\r\n\tSupporting fundamental research to understand electron transfer between biological and synthetic systems, enabling new knowledge relevant for efficient bio‑electrocatalysis and future electro‑biotechnology applications.</li>\r\n\t<li><strong><a href=\"https://novonordiskfonden.dk/grant/challenge-programme-2027-harnessing-novel-earth-abundant-materials-for-sustainable-technologies/\">Harnessing Novel Earth‑Abundant Materials for Sustainable Technologies</a></strong><br>\r\n\tAiming to develop and understand novel materials based on Earth‑abundant elements, supporting sustainable technologies that reduce reliance on scarce or critical resources through interdisciplinary materials science and chemistry research.</li>\r\n</ul>\r\n(*) Applicants are only permitted to submit one proposal as main applicant across all four Challenge Programme 2027 calls.<br>\r\n<br>\r\n<strong>Funding</strong>: up to DKK 30 – 75 million ( ~ CHF 3.7-9.2 million)<br>\r\n<br>\r\n<strong>Duration</strong>: up to 6 years<br>\r\n<br>\r\n<strong>Eligibility:</strong> Applications must be submitted by an established research leader leading a consortium of 2–4 research groups (main applicant plus 1–3 co‑applicants), with the main applicant employed at a European (EU, Schengen Area or UK) host institution. At least one applicant (main or co‑applicant) must be employed at a Danish university, hospital or non‑profit research organisation.<br>\r\n<br>\r\n<strong>How to Apply</strong>: Applications should be submitted using the foundation’s online platform <a href=\"https://norma.novonordiskfonden.dk/\">NORMA</a>. The application process consists of two stages. Stage1 entails a short expression of interest limited to 10,000 characters with a preliminary budget and with a deadline of 07 October 2026. Several shortlisted applicants will be invited to Stage2 (notifications in December 2026), in which the applicants will be asked to submit an application with a detailed project proposal of 30,000 characters. These full proposals will be due on 10 February 2027.<br>\r\n<br>\r\n<strong>Deadline:</strong> 07-October-2026<br>\r\n<br>\r\n<strong>Further information</strong>\r\n\r\n<ul>\r\n\t<li>More detailed information is available via the links embedded in the titles of the individual calls</li>\r\n\t<li>The application portal can be found <a href=\"https://norma.novonordiskfonden.dk/\">here</a></li>\r\n\t<li>For any other questions, please contact the <a href=\"mailto:[email protected]\">Research Office</a></li>\r\n</ul>", "image_description": "", "creation_date": "2026-04-27T15:39:12", "last_modification_date": "2026-04-27T15:39:12", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "", "url_place_and_room": "", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "", "contact": "<a href=\"mailto:[email protected]\">Research Office</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120556/", "category": { "id": 16, "code": "PROP", "fr_label": "Appel à proposition", "en_label": "Call for proposal", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/8/?format=api", "https://memento.epfl.ch/api/v1/mementos/140/?format=api", "https://memento.epfl.ch/api/v1/mementos/5/?format=api", "https://memento.epfl.ch/api/v1/mementos/6/?format=api", "https://memento.epfl.ch/api/v1/mementos/27/?format=api" ] }, { "id": 69765, "title": "ISIC Faculty Lunch", "slug": "isic-faculty-lunch-7", "event_url": "https://memento.epfl.ch/event/isic-faculty-lunch-7", "visual_url": "https://memento.epfl.ch/image/31251/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/31251/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/31251/max-size.jpg", "lang": "en", "start_date": "2026-11-13", "end_date": "2026-11-13", "start_time": "12:00:00", "end_time": "14:00:00", "description": "<strong>Agenda</strong><br>\r\n12:10 – 12:30 25th Institute Anniversary<br>\r\n12:30 – 14:00 Standing Lunch", "image_description": "", "creation_date": "2025-09-09T11:23:01", "last_modification_date": "2026-03-03T09:22:00", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "Copernic", "url_place_and_room": "https://plan.epfl.ch/?room==CE%201%20711.1", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "", "organizer": "<a href=\"https://www.epfl.ch/schools/sb/research/isic/\">Institute of Chemical Sciences and Engineering – ISIC</a>", "contact": "<a href=\"https://people.epfl.ch/marta.ruizcumi\">Marta Ruiz Cumi</a>", "is_internal": "True", "theme": "", "vulgarization": { "id": 2, "fr_label": "Public averti", "en_label": "Informed public" }, "registration": { "id": 2, "fr_label": "Sur invitation", "en_label": "Invitation required" }, "keywords": "ISICIntranet", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/117576/", "category": { "id": 1, "code": "CONF", "fr_label": "Conférences - Séminaires", "en_label": "Conferences - Seminars", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/14/?format=api" ] }, { "id": 69172, "title": "Dynamic Decisions and Temporal Frictions in On-Demand Mobility", "slug": "dynamic-decisions-and-temporal-frictions-in-on-d-2", "event_url": "https://memento.epfl.ch/event/dynamic-decisions-and-temporal-frictions-in-on-d-2", "visual_url": "https://memento.epfl.ch/image/33200/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33200/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33200/max-size.jpg", "lang": "en", "start_date": "2026-06-22", "end_date": "2026-06-22", "start_time": "10:30:00", "end_time": "11:30:00", "description": "<strong>ABSTRACT</strong><br>\r\nApp-based, on-demand transport systems have transformed urban mobility by enabling real-time coordination between vehicles and users. Yet behind this flexibility lies a fundamental tension: operational decisions that appear beneficial in the present can deteriorate the future state of the system. This talk explores these temporal frictions in assigned on-demand systems—where passengers and vehicles are matched before meeting—and how they shape the performance and reliability of shared mobility services.<br>\r\nFirst, we show how assignment decisions evolve through what we term the Increasing Gap Dynamics, a negative feedback cycle through which vehicles progressively concentrate in space, reducing system efficiency over time. We then examine how a tension between efficiency and reliability emerges: while highly dynamic operations can improve short-term efficiency and flexibility, they may also increase unreliability by exposing passengers to future, uncertain requests. We discuss how this tension manifests both in routing decisions and in the selection of pickup and dropoff locations, and show how carefully designed anticipatory techniques can help reconcile these competing objectives.<br>\r\n<br>\r\n <br>\r\n<strong>SHORT BIO</strong><br>\r\nDr Andrés Fielbaum is a Senior Lecturer in Transport Engineering at the University of Sydney and a DECRA Fellow of the Australian Research Council. His work lies at the intersection of transport systems and applied mathematics, with a focus on public transport, on-demand mobility, and developing analytical models to inform system design and operations. He completed his PhD in Systems Engineering at Universidad de Chile in 2019 and held a postdoctoral appointment at TU Delft between 2019-2023.<br>\r\n<br>\r\nDr Fielbaum has authored over 35 peer-reviewed journal articles in leading outlets and serves as an Associate Editor for Transportation Research Part B: Methodological, and the Journal of Intelligent Transportation Systems.<br>\r\n<br>\r\n ", "image_description": "", "creation_date": "2025-05-15T16:13:27", "last_modification_date": "2026-05-13T08:28:12", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "GC B1 10", "url_place_and_room": "https://plan.epfl.ch/?room==GC%20B1%2010", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "Dr Andrés Fielbaum", "organizer": "HOMES - Prof. Kenan Zhang", "contact": "Prof. Kenan Zhang<br>\r\nAdministrative: Mélanie Thuillard", "is_internal": "False", "theme": "", "vulgarization": { "id": 2, "fr_label": "Public averti", "en_label": "Informed public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/116691/", "category": { "id": 1, "code": "CONF", "fr_label": "Conférences - Séminaires", "en_label": "Conferences - Seminars", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/4/?format=api", "https://memento.epfl.ch/api/v1/mementos/6/?format=api", "https://memento.epfl.ch/api/v1/mementos/8/?format=api", "https://memento.epfl.ch/api/v1/mementos/27/?format=api", "https://memento.epfl.ch/api/v1/mementos/433/?format=api" ] }, { "id": 71836, "title": "Nanoscale analysis of membrane proteins in native milieu", "slug": "nanoscale-analysis-of-membrane-proteins-in-nativ-2", "event_url": "https://memento.epfl.ch/event/nanoscale-analysis-of-membrane-proteins-in-nativ-2", "visual_url": "https://memento.epfl.ch/image/33156/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33156/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33156/max-size.jpg", "lang": "en", "start_date": "2026-07-07", "end_date": "2026-07-07", "start_time": "15:00:00", "end_time": "16:00:00", "description": "<strong>Abstract: </strong>In this seminar, Moitrayee Bhattacharyya will present her lab’s work on developing experimental platforms to resolve the molecular and functional organization of membrane proteins in their native environments and applying these tools to study membrane proteins that regulate neuronal signaling and neurodegeneration, chronic pain, and cancer. High-resolution quantitative measurements of the oligomeric organization of membrane proteins in native membranes, and how they change under different conditions, are indispensable for understanding membrane protein biology. Her lab reported a single-molecule technique, Native-nanoBleach, to determine the oligomeric distribution of membrane proteins from native membranes at ~10 nm spatial resolution and at endogenous levels of expression. They applied Native-nanoBleach to quantify the oligomerization status of structurally and functionally diverse membrane proteins. Her team has now extended this general technique to organellar membrane proteins and membrane contact sites in the context of neurodegeneration and rare developmental diseases. This general experimental pipeline will usher in a new era of studying membrane protein organization in their native membrane environments under various physiological and clinical conditions.<br>\r\n \r\n<div><strong>Bio</strong>: Moitrayee Bhattacharyya received her Ph.D. in Computational Biophysics at the Indian Institute of Science, Bangalore, where she used molecular dynamics simulations and network theory to study allosteric communication in protein complexes. She transitioned into experimental biology during her postdoctoral studies at the University of California, Berkeley, as a Human Frontiers Science Program Long Term Fellow. Here, she used structural biology and single-molecule microscopy to study the molecular mechanism of regulation in a calcium/calmodulin-dependent protein kinase that is critical for learning and memory. She started her lab at Yale University in the summer of 2020. One focus is to develop broad-impact technological platforms that enable high-resolution studies of membrane proteins in native membranes, in her lab and beyond. Her lab also applies these technologies in conjunction with established biophysical and structural methods to understand the molecular mechanisms of membrane-localized signaling in chronic pain and neurodegenerative diseases.</div>", "image_description": "", "creation_date": "2026-05-08T14:43:44", "last_modification_date": "2026-05-11T09:28:30", "link_label": "", "link_url": "https://medicine.yale.edu/profile/moitrayee-bhattacharyya/", "canceled": "False", "cancel_reason": "", "place_and_room": "Conference room SV.1717", "url_place_and_room": "https://www.epfl.ch/schools/sv/it/sv-rooms/#SV1717", "url_online_room": "", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "Moitrayee Bhattacharyya, Ph.D. Assistant Professor, Department of Pharmacology, Yale University School of Medicine ", "organizer": "Institute of Bioengineering, EPFL", "contact": "Prof. Florian Schueder", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120702/", "category": { "id": 1, "code": "CONF", "fr_label": "Conférences - Séminaires", "en_label": "Conferences - Seminars", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/1/?format=api", "https://memento.epfl.ch/api/v1/mementos/5/?format=api", "https://memento.epfl.ch/api/v1/mementos/6/?format=api", "https://memento.epfl.ch/api/v1/mementos/8/?format=api", "https://memento.epfl.ch/api/v1/mementos/9/?format=api", "https://memento.epfl.ch/api/v1/mementos/111/?format=api" ] }, { "id": 71919, "title": "MEchanics GAthering –MEGA- Seminar: Navigating the shift from academia to the industrial sector", "slug": "mechanics-gathering-mega-seminar-navigating-the-sh", "event_url": "https://memento.epfl.ch/event/mechanics-gathering-mega-seminar-navigating-the-sh", "visual_url": "https://memento.epfl.ch/image/33236/200x112.jpg", "visual_large_url": "https://memento.epfl.ch/image/33236/720x405.jpg", "visual_maxsize_url": "https://memento.epfl.ch/image/33236/max-size.jpg", "lang": "en", "start_date": "2026-05-28", "end_date": "2026-05-28", "start_time": "13:05:00", "end_time": "14:00:00", "description": "<strong>Abstract:</strong> What does it mean to move from an academic career into industry after a PhD or postdoctoral experience? Which skills transfer naturally, which challenges emerge along the way, and how can scientists prepare for the shift?<br>\r\nIn this seminar, two speakers from different scientific backgrounds will share their personal journeys from academia to industry.They will offer honest, complementary perspectives on leaving university research, exploring the practical realities, challenges, and distinct working cultures of the industry sector.<br>\r\nThrough their experiences, participants will gain practical insights into recruitment processes, workplace expectations, and the opportunities available to scientists in industry.<br>\r\n<br>\r\n<strong>Tristans's Bio: </strong>I got a PhD in aeronautical Engineering in 2011 from KTH, Stockholm, Sweden, with a thesis on Aerodynamics simulations of ground vehicles in unsteady crosswind.<br>\r\nAfter this, I worked with various Formula One teams from 2012 to 2025, starting as a CFD Engineer and moving to an Aerodynamicist role in 2014. Between 2022 and 2025, I have been involved in the development of the British Challenger for the 37th America’s Cup (iconic Yacht competition), leading the Fluid Dynamics team towards the end.<br>\r\nSince summer 2025, I am a scientist at LFMI on a FNS funded project “Why do albatrosses and pelicans morph to an arch-shaped wing configuration when gliding near the water surface?”.<strong> <br>\r\n<br>\r\nBertrand's Bio: </strong>After completing an Aerospace Engineering degree from ISAE-SUPAERO (Toulouse, France) and Université de Toulouse, where I specialized on Earth observation, numerical modeling and climate science, I completed my PhD at Météo-France's Center for Snow Studies (CEN, Grenoble, France). I worked for four years as a postdoc at the Snow and Avalanche Research Lab (SLF, Davos, Switzerland), at the interface between research and operational flood forecasting. Since 2025, I joined Hydrique Ingénieurs, in Lausanne, where I do numerical modeling for various projects related to water resources management and flood forecasting.<br>\r\n<br>\r\nThe talk will be followed by an informal apero!<br>\r\n ", "image_description": "", "creation_date": "2026-05-21T15:33:37", "last_modification_date": "2026-05-22T16:07:51", "link_label": "", "link_url": "", "canceled": "False", "cancel_reason": "", "place_and_room": "ME B1 10", "url_place_and_room": "https://plan.epfl.ch/?room==ME%20B1%2010", "url_online_room": "https://epfl.zoom.us/j/68096021948?pwd=DiE8amDIwYw1u3VtW2xWNGKtioKL2y.1", "spoken_languages": [ "https://memento.epfl.ch/api/v1/spoken_languages/2/?format=api" ], "speaker": "<a href=\"https://people.epfl.ch/tristan.favre?lang=en\">Tristan Favre</a> (<a href=\"https://lfmi.epfl.ch/\">LFMI</a>, EPFL), Bertrand Cluzet (<a href=\"https://hydrique.ch/fr\">Hydrique Ingénieurs</a>)", "organizer": "MEGA.Seminar Organizing Committee", "contact": "<a href=\"http://[email protected]/\">Aliénor Riviere</a>, <a href=\"http://[email protected]/\">Danick Lamoureux</a>, <a href=\"http://[email protected]/\">Jacopo Bilotto</a>", "is_internal": "False", "theme": "", "vulgarization": { "id": 1, "fr_label": "Tout public", "en_label": "General public" }, "registration": { "id": 3, "fr_label": "Entrée libre", "en_label": "Free" }, "keywords": "Career Development, Transferable Skills", "file": null, "icalendar_url": "https://memento.epfl.ch/event/export/120824/", "category": { "id": 1, "code": "CONF", "fr_label": "Conférences - Séminaires", "en_label": "Conferences - Seminars", "activated": true }, "academic_calendar_category": null, "domains": [], "mementos": [ "https://memento.epfl.ch/api/v1/mementos/232/?format=api", "https://memento.epfl.ch/api/v1/mementos/245/?format=api" ] } ] }
